Tempus AI, Inc. is a U.S.-based healthcare technology company that combines diagnostic testing with data and software products for clinical and research use. Its business centers on genomics testing, de-identified data licensing, clinical trial matching, and AI-enabled applications built around a large clinical and molecular dataset.
−17,4 %
−19,3 %
+83,4 %
3.13
3.00
| % | |
|---|---|
| Genomics / Diagnostics | 75% Laboratory testing services including oncology, PCR profiling, hereditary cancer risk, and rare-disease profiling. |
| Data and Services | 25% De-identified data licensing, analytical services, and clinical trial matching for biopharma customers. |
| AI Applications / Next | 0% AI-driven applications that route patients to therapy options and support clinical and research workflows. |
Tempus sells primarily to healthcare providers and life sciences companies. Physicians, hospitals, genetic counselors,...
Physicians, hospital systems, and genetic counselors buy genomics tests and clinical tools to support diagnosis and treatment decisions.
Drug makers license de-identified data and use trial-matching services to improve research, development, and patient recruitment.
Biotech customers buy data, analytics, and matching services to support discovery and clinical development programs.
Universities and research centers use testing and datasets for translational research and clinical studies.
Tempus is primarily a North American business, with the majority of revenue generated in North America...
Tempus focuses on expanding adoption across both product lines by increasing use among existing customers and adding...
Higher utilization and upsell activity improve monetization of the installed base and strengthen retention.
New applications extend the platform and create additional monetization paths from the same underlying data asset.
More clinical and molecular data can improve test performance and make the platform more valuable to researchers and clinicians.
Tempus depends on continued access to de-identified patient data, customer renewals, and successful commercialization...
Data and services revenue depends on renewals and expansion of existing agreements, and a few customers can represent a meaningful share of revenue.
The platform’s value and monetization depend on continued access to large datasets and the ability to use them commercially.
AI products can create liability or reputational harm if outputs are inaccurate, biased, or based on improperly used data.
Diagnostics adoption depends on coverage and reimbursement decisions by commercial and government payers.
Competitors may have greater resources, broader sales forces, or alternative diagnostic technologies.
MMS · Services-Business Services, NEC
MAXIMUS is a U.S.-based government services contractor that designs and operates tech-enabled programs for federal, state, local, and international public agencies.
PSNL · Services-Medical Laboratories
LNAI · Pharmaceutical Preparations
RXRX · Biological Products, (No Diagnostic Substances)
Recursion Pharmaceuticals is a U.S.-based clinical-stage TechBio company that uses its Recursion Operating System to discover and develop medicines.
IQV · Services-Commercial Physical & Biological Research
MDAI · Surgical & Medical Instruments & Apparatus
: 29/04/2026